The AI engine is offline (last seen Aug 12, 05:02 UTC). Scores are shown as of their timestamps; new theses and refreshes are queued and run the moment it returns.

Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials
← back
healthcare · sector mood
2025
year mood -0.16 · -0.30 to -0.04 across 12 mo
Monthly mood
bearish −1 +1 bullish
-0.5 -0.25 0 +0.25 +0.5 Jan Feb Mar -0.04 Apr -0.30 May Jun Jul Aug Sep Oct Nov Dec
month values ▾
JanFebMarAprMayJunJulAugSepOctNovDec
-0.10-0.20-0.04-0.30-0.14-0.20-0.20-0.20-0.20-0.10-0.10-0.10

UnitedHealth guidance cut and DOJ probe; managed-care crash, tariff threats

How this mood is scored ▾
Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 06, 2026
Top healthcare stories of 2025
Mar
Doctors Warn Against RFK Jr.'s Measles Messaging Amid Outbreak npr.org →

Two deaths in a measles outbreak in West Texas and New Mexico have heightened concerns as Health Secretary Robert F. Kennedy Jr. emphasizes vitamin A and nutrition over vaccination in public messaging. Doctors warn this approach spreads misinformation, distracts from vaccination efforts, and could undermine public health responses, risking increased transmission and preventable illness.

May
Trump orders drug prices tied to lowest global rates cnbc.com →

President Trump signed an executive order to align U.S. drug prices with lower international rates, targeting medications with the largest cost disparities, including GLP-1 drugs. The policy, facing legal and implementation challenges, could pressure drugmakers' profits and innovation, while boosting scrutiny of foreign pricing practices; however, markets shrugged, with major pharma stocks rising post-announcement.